摘要
目的比较齐拉西酮与利培酮治疗女性首发精神分裂症的疗效及安全性。方法将68例女性首发精神分裂症患者随机分为齐拉西酮与利培酮组各34例,分别给予齐拉西酮和利培酮治疗(齐拉西酮82.20±4.04mg/d和利培酮3±1.20mg/d),疗程均为8周。分别于治疗前及治疗第1,2,4,8周采用阳性与阴性症状量表(PANSS)评定疗效;以治疗中出现的症状量表(TESS)评定不良反应。结果齐拉西酮组显效率和有效率分别为61.76%和79.41%,利培酮组分别为58.82%和76.47%,两组比较,差异无统计学意义(P>0.05)。两组治疗后PANSS评分均较治疗前明显下降(P<0.05或P<0.01),齐拉西酮组阴性症状因子分在治疗4和8周时[分别为(15.4±2.0)和(12.8±3.2)]显著低于利培酮组[分别为(20.8±2.2)和(17.7±7.6)]分,两组比较,差异有统计学意义(P<0.05或P<0.01)。结论齐拉西酮是一种安全有效的抗精神病药物,对阴性症状有显著的改善作用。
Objective To compare the efficacy and side effects of ziprasidone and risperidone in treating patients of female with first-episode schizophrenia. Method 68 patients of schizophrenia were treated with ziprasidone（n=34）or risperidone（n=34）randomly,for 8 weeks.The efficacy was assessed with the positive and negative symptoms scale（PANSS）,and the safety was assessed with treatment emergent symptoms scale（TESS） before treatment and at the ends of week 1,2,4,and 8 treatment,respectively. Results The significantly effective rate and effective rate of ziprasidone were 61.76% and 79.41%,and of risperidone were 58.82% and 76.47% and respectively,and there were no significant differences between two groups（P0.05）,ziprasidone group showed lower negative symptom score at week（15.4±2.0 vs 12.8±3.2,P0.05）and at weed 8（20.8±2.2 vs 17.7±7.6,P0.01） than risperidone group,although the scores decreased after 4 and 8 weeks. Conclusion Ziprasidone is effective and safe antipsychotic drug with more showing significant improvement compared with risperidone in negative symptoms.
出处
《四川精神卫生》
2012年第2期103-105,共3页
Sichuan Mental Health
